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African trypanosomes cause lethal and neglected tropical diseases,
known as sleeping sickness in humans and nagana in animals.
Current therapies are limited, but fortunately, promising therapies
are in advanced clinical and veterinary development, including
acoziborole (AN5568 or SCYX-7158) and AN11736, respectively.
These benzoxaboroles will likely be key to the World Health
Organization’s target of disease control by 2030. Their mode of
action was previously unknown. We have developed a high-
coverage overexpression library and use it here to explore drug
mode of action in Trypanosoma brucei. Initially, an inhibitor with a
known target was used to select for drug resistance and to test
massive parallel library screening and genome-wide mapping;
this effectively identified the known target and validated the
approach. Subsequently, the overexpression screening approach
was used to identify the target of the benzoxaboroles, Cleavage
and Polyadenylation Specificity Factor 3 (CPSF3, Tb927.4.1340).
We validated the CPSF3 endonuclease as the target, using inde-
pendent overexpression strains. Knockdown provided genetic
validation of CPSF3 as essential, and GFP tagging confirmed the
expected nuclear localization. Molecular docking and CRISPR-
Cas9-based editing demonstrated how acoziborole can specifically
block the active site and mRNA processing by parasite, but not
host CPSF3. Thus, our findings provide both genetic and chemical
validation for CPSF3 as an important drug target in trypanosomes
and reveal inhibition of mRNAmaturation as the mode of action of
the trypanocidal benzoxaboroles. Understanding the mechanism
of action of benzoxaborole-based therapies can assist develop-
ment of improved therapies, as well as the prediction and moni-
toring of resistance, if or when it arises.
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African trypanosomes are transmitted by tsetse flies and causedevastating and lethal diseases: sleeping sickness in humans
and nagana in livestock. The closely related parasites that cause
acute and chronic forms of the human disease in Eastern and
Western Africa are Trypanosoma brucei rhodesiense and Trypa-
nosoma brucei gambiense, respectively (1). These parasites also
infect other mammals, whereas Trypanosoma congolense, Try-
panosoma vivax, and Trypanosoma brucei brucei also cause live-
stock disease (2). The vast majority of human cases are caused by
T. b. gambiense, which progresses from a hemolymphatic first-
stage infection to a typically lethal second stage, when parasites
enter the central nervous system.
There is no effective vaccine against African trypanosomes.
Current drugs against the first-stage disease, pentamidine and
suramin, are ineffective if parasites have entered the central
nervous system, which is frequently the case at the point of di-
agnosis. For second-stage disease, the central nervous system-
penetrant drugs, melarsoprol or nifurtimox and eflornithine, are
required (3). Melarsoprol suffers from significant toxicity and
drug resistance, and its use is now limited (4). The current
nifurtimox-eflornithine combination therapy (NECT) is effec-
tive, but expensive, and administration is complex, requiring
hospitalization, trained staff, and multiple drug infusions, which
may not be sustainable (5). Drug resistance also threatens the
usefulness of current chemotherapy, and chemoprophylaxis for
animal trypanosomiasis with diminazene aceturate (Berenil) or
isometamidium (Samorin) (2).
Despite the challenges, cases of sleeping sickness have declined
in recent years, and the disease is now a World Health Organi-
zation (WHO) target for elimination as a public health problem
by 2020 (defined as <1 case/10,000 inhabitants in 90% of endemic
foci). A further target is to stop disease transmission by 2030 (6).
Attainment of these goals likely depends on the success of ther-
apies currently in clinical and veterinary development (3), as it will
also be important to control reservoirs in animals (7). Safe, af-
fordable, oral therapies that are effective against both stages of
the human disease and effective drugs against the animal disease
would be transformative. The former could also remove the need
for painful and cumbersome lumbar puncture diagnosis to con-
firm the second stage of human infection.
Significance
The World Health Organization’s target is to stop sleeping
sickness transmission by 2030. Current challenges include a
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identify the benzoxaborole target. These drugs bind the ac-
tive site of CPSF3, an enzyme that processes messenger RNA and
facilitates gene expression. Our studies validate the gain-of-
function approach and reveal an important drug target. These
findings will facilitate development of improved therapies and
prediction and monitoring of drug resistance.
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At the end of the last century, there were no new drugs in the
pipeline. There are now two new and promising oral drugs in
clinical trials against sleeping sickness, acoziborole (AN5568 or
SCYX-7158) (8, 9) and fexinidazole (10), and one in trials
against nagana, AN11736 (11). However, the relevant cellular
targets of these drugs remain unknown, hindering further de-
velopment, exploitation of related molecules, and understanding
of toxicity or resistance mechanisms.
Both acoziborole and AN11736 are benzoxaboroles (8, 9,
11). Acoziborole, developed by Anacor and Scynexis, emerged
in 2011 as an effective, safe, and orally active preclinical can-
didate against T. b. gambiense, T. b. rhodesiense, and T. b.
brucei, including melarsoprol-resistant strains, and against both
disease stages (8, 9). A phase 1 clinical trial was successfully
completed in 2015, and a phase 2/3 trial was initiated in 2016
by the Drugs for Neglected diseases initiative (www.dndi.org/
diseases-projects/portfolio/scyx-7158/). AN11736 is effective
against both T. congolense and T. vivax, shows great promise for
the treatment of animal trypanosomiasis in early development
studies (11). Another benzoxaborole, AN4169 (SCYX-6759),
displays activity against both T. brucei (12) and Trypanosoma
cruzi, the South American trypanosome (13, 14), which causes
Chagas disease. In addition, the benzoxaborole, DNDI-6148,
was recently approved for phase 1 assessment and is a prom-
ising candidate for treating both visceral and cutaneous leish-
maniasis caused by Leishmania parasites, another group
of trypanosomatids (www.dndi.org/diseases-projects/portfolio/
oxaborole-dndi-6148/). Related back-up benzoxaboroles are also
available if needed.
Oxaboroles display antiviral, antibacterial, antifungal, anti-
protozoal, and anti-inflammatory activity. Known targets include
a viral protease (15), bacterial β-lactamase (16), bacterial leucyl-
tRNA synthetase (17), and apicomplexan CPSF3, a metallo
β-lactamase (18, 19). Tavaborole (AN2690 or Kerydin) is a
topical treatment approved by the US Food and Drug Admin-
istration for toenail onychomycosis (20) that targets the fungal
cytoplasmic leucyl-tRNA synthetase (21). Oxaboroles are also
potential antihypertensive rho-activated kinase inhibitors (22)
and anti-inflammatory phosphodiesterase inhibitors for the
treatment of psoriasis (23). Genomic and proteomic approaches,
using oxaborole-1, a close analog of acoziborole, previously yielded
lists of candidate genes implicated in the antitrypanosomal mode of
action (24), whereas metabolomic analysis after acoziborole expo-
sure indicated perturbation of S-adenosyl-L-methionine metabolism
(25), but the trypanocidal targets of acoziborole and AN11736
remained unknown.
RNA interference library screens have been very effective for
identifying drug resistance mechanisms in trypanosomes, partic-
ularly because of defects in drug uptake or metabolism (26), but
this loss-of-function approach does not typically reveal the target
or targets of a drug. Indeed, RNA interference screens re-
cently revealed a prodrug activation mechanism for a class of
aminomethyl-benzoxaboroles, including AN3057, involving a T. b.
brucei aldehyde dehydrogenase, but not the target (27). A gain-of-
function approach is more likely to identify drug targets, and proof
of concept has been achieved using an overexpression library in
T. b. brucei (28). However, the use of relatively short inserts
(∼1.2 kbp) and fusion with a common RNA-binding domain at the
N termini (29) precluded the overexpression of full-length native
proteins, many proteins larger than ∼50 kDa, or protein targeting
to the secretory pathway or mitochondrion (28). A related over-
expression approach with the potential to identify drug targets,
Cos-seq, has also been described for Leishmania (30).
We assembled a T. b. brucei inducible overexpression library
for full-length genes and with optimized genome coverage. Here,
we describe and validate high-throughput overexpression, com-
bined with massive parallel screening, and use the approach to
identify the common target of several benzoxaboroles, including
acoziborole and AN11736. The trypanocidal benzoxaborole
target is the nuclear mRNA processing endonuclease, cleavage
and polyadenylation specificity factor 3 (CPSF3/CPSF73/Ysh1).
Results
A High-Coverage T. b. brucei Overexpression Library.Our goal was to
develop an unbiased bloodstream-form T. b. brucei over-
expression library with optimized genome coverage. We first
assembled the overexpression construct, pRPaOEX, and then
constructed a library using T. b. brucei genomic DNA partially
digested with Sau3AI (Fig. 1A). The T. b. brucei genome com-
prises 46% GC content (31), so Sau3AI sites (GATC) occur once
every ∼256 bp. The genome has only two known introns (32),
such that the vast majority of genes comprise a single protein-
coding exon with an average size of 1,592 bp; the core genome is
also otherwise compact with average intergenic regions of 1,279 bp
(31). Partially digested 3–10-kbp genomic DNA fragments
were cloned in pRPaOEX, using a BbsI semifilling strategy to
optimize the library assembly step (Fig. 1A); 99.4% of annotated
coding sequences are <10 kbp. Our approach places the genomic
DNA fragments under the control of a tetracycline-inducible
ribosomal RNA (RRNA) promoter (Fig. 1A), an RNA poly-
merase I promoter that can drive high-level expression of protein
coding genes in trypanosomes (33); transcription by RNA polymerase
I provides 40-fold stronger transcription than RNA polymerase II,
which produces the vast majority of the natural transcriptome
(34). The resulting plasmid library comprised >20 million clones,
from which 26 (87%) of 30 analyzed contained inserts in the
expected size-range (SI Appendix, Fig. S1A).
To establish a T. b. brucei library, we used a system for high-
efficiency transfection previously used to assemble other li-
braries in bloodstream-form cells (35). This involves I-SceI
meganuclease-mediated induction of a break at the chromo-
somal integration target site for pRPaOEX. I-SceI was also used
to linearize the plasmid library before transfection (Fig. 1A),
further facilitating optimal genome coverage (Materials and
Methods). The number of T. b. brucei clones recovered was es-
timated to be ∼1 million, equating to a library with ∼eightfold
genome coverage (fourfold in each direction); 17 of 22 T. b.
brucei clones analyzed (77%) contained inserts in the expected
size range, as determined using a long-range PCR assay (SI
Appendix, Fig. S1B).
The workflow for library construction and screening is illus-
trated in Fig. 1B. Before screening, we first carried out a quality-
control step, both to determine the integrity and coverage of the
T. b. brucei library and to establish the screening protocol (Fig.
1B). Briefly, genomic DNA was extracted from the pooled li-
brary and fragments were amplified from the integrated over-
expression constructs using long-range PCR, these products were
deep-sequenced, and the reads were mapped to the reference
genome (Fig. 1B); pRPaOEX-derived barcodes were included to
precisely map overexpressed fragments and to determine their
orientation. This indicated that >95% of genes are included in
the library, and a representative 35-kbp region of the genome
reveals excellent coverage, with fragment junctions (barcoded
reads) corresponding to the expected locations of Sau3AI sites
(Fig. 1C). The barcodes also effectively reveal fragment orien-
tation with respect to the RRNA promoter in the overexpression
construct. As expected, half of the fragments are in the for-
ward direction and half are in the reverse direction (Fig. 1C,
color coding).
Drug-Target Identification Provides Validation for the Overexpression
Library. Overexpression or gain of function of a drug target can
produce drug-resistant cells by increasing the pool of functional
protein, possibly by reducing intracellular free drug concentra-
tion through binding or through both mechanisms simulta-
neously. Other resistance mechanisms are also possible (36). In









the first instance, we wanted to determine whether our screening
approach could identify a known drug target. There are very few
inhibitors with known targets in trypanosomes, and therefore we
used the well-characterized, experimental N-myristoyltransferase
inhibitor, DDD85646 (37). The library was induced with tetra-
cycline for 24 h before selection for 9 d with 5.2 nM DDD85646
(∼2 × EC50, effective concentration of drug to reduce cell growth
by 50%). Drug-selected cells displayed the expected reduced
growth relative to a nonselected, but induced, control population
(Fig. 1D). Because integrated, overexpressed fragments are
replicated within T. b. brucei genomic DNA, those that confer
resistance will be over-represented after drug selection.
Following the scheme presented here (Fig. 1B), a genome-
scale map of hits was generated from the DDD85646 screen
(Fig. 1E); the map includes the full nonredundant set of ∼7,500
genes. This screen revealed a single major hit on chromosome 10
(Fig. 1E) comprising >66% of all mapped reads. A closer inspec-
tion revealed the barcoded junctions of a 3.982-kbp fragment. This
fragment (>2.7 million mapped reads) encompassed one complete
protein coding sequence (CDS) (SI Appendix, Table S1) that en-
codes N-myristoyltransferase (Fig. 1E, Inset; Tb927.10.14240,
NMT), the known target of DDD85646 (37). The barcodes (green
and black peaks) reveal the orientation of the gene, and indeed, as
expected, they show a sense orientation of the coding sequence with
respect to the RRNA promoter driving overexpression.
Our approach also presents an opportunity to uncover biology
beyond an immediate drug target. In the case of the NMT inhibitor,
we asked whether overexpression of essential NMT-substrates
would confer drug-resistance. Global profiling revealed 53 high-
confidence candidate N-myristoylated proteins in T. brucei (38).
Only four additional fragments with intact CDSs registered on the
genome-scale map for the DDD85646-screen, and one of these
(>54,000 mapped reads) encompassed an array of almost identical
genes on chromosome 9 (Fig. 1E and SI Appendix, Table S1).
These genes encode the N-myristoylated ADP ribosylation factor 1
(ARF1), an essential Golgi protein required for endocytosis (39).
Notably, both ARF1 knockdown (39) and DDD85646 exposure/
NMT-inhibition (37) yield the same endocytosis-defective “BigEye”
phenotype (40).
Thus, the results of this screen support the view that DDD85646
is a specific inhibitor of T. b. brucei NMT, and also that ARF1 is
a major NMT substrate that contributes to lethality when N-
myristoylation, membrane association of the ARF1 protein,
and endocytosis, are defective. Taken together, this provides
excellent validation for the high-throughput overexpression li-
brary and for the genome-wide screening approach.
Screens with Benzoxaboroles Identify CPSF3 as the Probable Target.
The overexpression library was induced as described here and se-
lected for 8 d with 1 μM acoziborole (∼2 × EC50; SI Appendix, Fig.
S2 A and B). Sequencing and mapping of overexpressed inserts
revealed another remarkably specific and dominant hit on the
genome-scale map; >72% of all reads mapped to a single region on
chromosome 4 (Fig. 2A and SI Appendix, Table S2; >6.1 million
mapped reads). Only one additional fragment that registered on
this map encompassed an intact CDS, encoding a hypothetical
protein (Tb927.10.5630) on chromosome 10 (Fig. 2A and SI Ap-
pendix, Table S2), but this fragment registered <1% of the reads
mapped to the major hit fragment, and so was not investigated
further. Closer inspection of the mapped reads on chromosome
4 revealed a single 4.276-kbp fragment encompassing one
complete 2.725-kbp CDS, Tb927.4.1340 (Fig. 2A and SI Ap-
pendix, Table S2). Tb927.4.1340 encodes a subunit of the cleav-
age and polyadenylation specificity factor complex (CPSF3; Fig.
2A, Inset). As earlier, the barcodes reveal the expected sense
orientation of the fragment with respect to the promoter.
A screen with a second benzoxaborole, AN4169/SCYX-6759,
active against both T. brucei (12) and T. cruzi (13, 14), for 8 d at
0.3 μM (∼2 × EC50; SI Appendix, Fig. S2 C and D), revealed the
same major hit as acoziborole, Tb927.4.1340/CPSF3 (Fig. 2B).
Once again, this hit was remarkably specific and dominant, with
no additional fragments registered on the genome-scale map in
this case (Fig. 2B and SI Appendix, Table S3).
Genetic Validation of CPSF3 as the Target of the Trypanocidal
Benzoxaboroles. The results presented here suggest acoziborole
and SCYX-6759 are specific inhibitors of T. b. brucei CPSF3. To
validate this hypothesis, we first generated independent T. b. brucei
strains for inducible overexpression of a C-terminal GFP-tagged
Fig. 1. Assembly and validation of the T. b. brucei
overexpression library. (A) Schematic illustrating the
pRPaOEX construct and library assembly. BLA, blasti-
cidin resistance gene; EP and RRNA arrows, procyclin
and RRNA promotors; HYG and RRNA, hygromycin
and ribosomal RNA targeting sequences; TetO, Tet
operator. Partially Sau3AI-digested gDNA and BbsI-
digested pRPaOEX were semifilled (red G’s and T’s).
Other relevant restriction sites are shown. (B) The
schematic illustrates T. b. brucei library construction,
screening, sequencing, and mapping. See SI Appen-
dix, SI Materials and Methods and text for further
details. Blue/pink or black/green barcodes indicate
fragments overexpressed in each direction. (C) A
representative 35-kbp genomic region indicates
coverage and fragment junctions corresponding to
Sau3AI sites (red). Barcoded reads as in B. Black bars,
CDSs, and two convergent polycistrons. (D) Growth
curves for the induced library with (closed circles) or
without (open circles) DDD85646. For the former,
arrows indicate the addition of Tet (blue) or Tet +
drug (black). (E) Genome-scale map of hits in the
DDD85646 screen (structure indicated). The arrow-
head and inset box indicate the primary hit, encod-
ing N-myristoyltransferase (NMT, green). Black bars
and black/green peaks as in B and C; gray, all
mapped reads.
9618 | www.pnas.org/cgi/doi/10.1073/pnas.1807915115 Wall et al.
version of CPSF3; inducible overexpression of CPSF3GFP was
confirmed by protein blotting (Fig. 3A). The EC50 values for
both acoziborole and SCYX-6759 were determined, revealing
that cells induced to overexpress CPSF3GFP displayed 5.7-fold
(Fig. 3B) and 4.2-fold resistance (Fig. 3C) relative to uninduced
cells, respectively. AN11736 is another benzoxaborole (SI Ap-
pendix, Fig. S3A) that shows great promise for the treatment of
animal African trypanosomiasis (11). We also determined the
AN11736 EC50 and found that cells induced to overexpress
CPSF3GFP displayed 3.6-fold resistance (Fig. 3D). Thus, CPSF3
is likely the target of both the human and animal trypanocidal
benzoxaboroles. Two additional benzoxaboroles (24, 27) (SI
Appendix, Fig. S3A), and the NMT-inhibitor (37) as a control,
were also tested. CPSF3GFP overexpressing cells displayed four-
fold resistance to oxaborole-1 (SI Appendix, Fig. S3B), 2.6-fold
resistance to AN3057 (SI Appendix, Fig. S3C), and as expected, no
resistance to the NMT inhibitor (Fig. 3E). Thus, CPSF3 appears
to be the target of all five benzoxaboroles tested: acoziborole,
SCYX-6759, AN11736, oxaborole-1, and AN3057.
Inducible RNA interference was used to further genetically
validate CPSF3 as a drug target. We suspected that CPSF3
knockdown would result in loss of viability, both because of its
role in RNA processing and because our genetic screens indicate
that the trypanocidal benzoxaboroles act by specifically targeting
CPSF3. In addition, prior genome-wide knockdown profiling
indicated that CPSF3 was among only 16% of genes that regis-
tered a significant loss of fitness in multiple experiments (41).
Inducible knockdown strains were assembled with a GFP-tagged
native allele of CPSF3, and inducible knockdown of CPSF3GFP
was confirmed by protein blotting (Fig. 3F). We observed a
major loss of fitness after CPSF3 knockdown (Fig. 3G). Thus,
T. b. brucei CPSF3 function is essential for viability.
The subcellular localization of CPSF3GFP was also examined in
cells expressing a native copy of CPSF3GFP (Fig. 3H) or over-
expressing CPSF3GFP (Fig. 3I). Consistent with its role in mRNA
maturation, we observed the expected nuclear localization for the
protein expressed from the native locus (Fig. 3H). In contrast, and
consistent with increased expression, we observed a more intense
nuclear CPSF3GFP signal and an additional, ectopic, cytoplasmic
signal in cells overexpressing the protein (Fig. 3I).
Acoziborole Specifically Blocks the Catalytic Site of Trypanosome
CPSF3. Analysis of CPSF3 sequences (Fig. 4A and SI Appendix,
Fig. S4A) revealed that the T. b. brucei and T. b. gambiense
proteins have identical metallo-β-lactamase and β-CASP do-
mains, which form the catalytic site, with only two amino acid
changes in the C-terminal domain. The livestock trypanosome,
T. congolense, also displays a high degree of conservation within
the metallo-β-lactamase and β-CASP domains, with only 10
conservative amino acid changes. Phylogeny reveals a cluster of
trypanosomatid sequences that is distinct from the human, api-
complexan, and Trichomonas vaginalis sequences (Fig. 4A). This
reflects divergence within the eukaryotic lineage, and may also
reflect the unusual mechanism of coupled polyadenylation and
transsplicing in trypanosomatids (42). Nevertheless, the domain
structure of CPSF3 is conserved from trypanosomatids to hu-
mans (Fig. 4A).
To further explore the interactions between the benzoxaboroles
and CPSF3, molecular docking studies were carried out (Fig.
4B). A T. brucei CPSF3 homology model was built using the
Thermus thermophilus TTHA0252 structure complexed with an
RNA substrate analog [PDB: 3IEM (43)] as a template. The
catalytic site is located at the interface of the metallo-β-lacta-
mase and β-CASP domains and comprises two zinc atoms co-
ordinated by a network of histidine and aspartic acid residues (SI
Appendix, Fig. S4A). In the model, the benzoxaborole moiety
occupies the same area as the phosphate of the RNA where the
two zinc atoms are present. The boron atom reacts with an ac-
tivated water molecule located at the bimetal center, leading to a
tetrahedral negatively charged species that mimics the transition
state of the phosphate of the RNA substrate (SI Appendix, Fig.
S4B). Arg270, which in the template is involved in the recogni-
tion of a second phosphate group, extends toward the ligand to
Fig. 2. Screens with benzoxaboroles identify CPSF3 as the putative target.
(A) Genome-scale map of hits in the acoziborole screen (structure indicated).
The arrowhead indicates the primary hit on chromosome 4. (Inset) Primary
hit, Tb927.4.1340 (green bar) encoding CPSF3. Other details as in Fig. 1E. (B)
Genome-scale map of hits in the SCYX-6759 screen. Other details as in A.
Fig. 3. Validation of T. b. brucei CPSF3 as the benzoxaborole target. (A)
Inducible overexpression (24 h +tetracycline, Tet) of CPSF3GFP was demon-
strated by protein blotting; two independent clones. Dose–response curves
with (open circles) and without (closed circles) overexpression of CPSF3GFP
for (B) acoziborole: EC50 no Tet, 0.38 ± 0.01 μM; +Tet, 2.19 ± 0.21 μM; 5.7-
fold shift; (C) SCYX-6759: EC50 no Tet, 0.17 ± 0.01 μM; +Tet, 0.71 ± 0.04 μM;
4.2-fold shift; (D) AN11736: EC50 no Tet, 0.63 ± 0.03 nM; +Tet, 2.29 ±
0.06 nM; 3.6-fold shift; (E) DDD85646: EC50 no Tet, 2.7 ± 0.05 nM; +Tet,
2.73 ± 0.17 nM. Error bars, ±SD; n = 3. (F) Inducible CPSF3 knockdown (24 h
+Tet) was demonstrated by protein blotting; two independent clones. (G)
Cumulative cell growth was monitored during CPSF3 knockdown. Wild-type
(open squares), no Tet (open circles), +Tet (closed circles); two of the three
latter populations display recovery after 3 d, as often seen in similar experi-
ments, resulting from disruption of the RNA interference cassette in some
cells. Error bars, ±SD; n = 3 independent knockdown strains. Fluorescence
microscopy reveals the subcellular localization of CPSF3GFP in cells expressing
(H) a native tagged allele or (I) an overexpressed copy. (Scale bars, 10 μM.)









establish a hydrogen bond interaction with the amide oxygen and
a cation-π interaction with the aromatic six-membered ring of the
benzoxaborole. The amide in position 6 of the benzoxaborole
ring directs the o-CF3, p-F phenyl ring of acoziborole toward the
area occupied by the terminal uracil base of the RNA substrate
and establishes a face-to-face π-stacking interaction with Tyr383.
The trifluoro methyl group and the fluorine atom on the phenyl
ring do not appear to establish a specific interaction.
The proposed mode of binding is consistent with the estab-
lished structure–activity relationships for this series (8, 9); spe-
cifically, the boron atom in the heterocyclic core is essential for
trypanocidal activity, and variation on the five-membered ring of
the benzoxaborole had a pronounced (>10-fold) effect, whereas
variation on the phenyl ring distal to the benzoxaborole core had
relatively little effect. The o-CF3 and p-F, however, provide a
favorable pharmacokinetic/dynamic profile that results in an
optimal response in the trypanosomiasis in vivo model. The
docking model is also consistent with structural data available for
other bimetal systems, such as benzoxaboroles binding to phos-
phodiesterase 4 (23), cyclic boronate binding to β-lactamases
(44), and the mechanism of action proposed for other RNA
degrading proteins of the metallo-β-lactamase family (43). Thus,
the proposed mode of acoziborole binding indicates a steric
block at the active site of trypanosome CPSF3 that perturbs the
pre-mRNA endonuclease activity.
Finally, we asked why acoziborole is well tolerated in animal
models and in humans, given the similarity between T. brucei
CPSF3 and human CPSF3 (SI Appendix, Fig. S4A). There are 26
residues within 5 Å of acoziborole in the model shown in Fig. 4B
(SI Appendix, Fig. S4A), and only four of these residues differ
between the T. brucei and human enzymes (Fig. 4C); all 26
residues are conserved among the trypanosomatids. The bulky
Tyr side-chain in the human enzyme, in place of Asn232, in
particular, presents a steric clash with the o-CF3, p-F phenyl
moiety of acoziborole (Fig. 4C). A Tyr residue is also present at
this position in the apicomplexan sequences, whereas a His
residue with a bulky side-chain is present at this position in the T.
vaginalis sequence (SI Appendix, Fig. S5). A clash with acozi-
borole in this position would likely prevent binding or disrupt the
geometry required for covalent bond formation. This hypothesis
was explored using CRISPR-Cas9-based editing (45) to mutate
T. b. brucei CPSF Asn232. The results suggested that an Asn232Tyr
edit was not tolerated, but we found that T. b. brucei expressing an
Asn232His substituted form of CPSF3 (SI Appendix, Fig. S5) were
fivefold resistant to acoziborole (Fig. 4D). As expected, a His
residue in place of Asn232 in our docking model, similar to the Tyr
residue in the human enzyme, presents a steric clash with acoziborole
(Fig. 4E). Thus, specific structural differences between trypanosome
and host CPSF3 offer an explanation for the safety profile and
selective activity of acoziborole.
Discussion
Phenotypic screening is a powerful strategy in drug discovery that
yields many anti-infective lead compounds for potential devel-
opment. The targets and mode of action of those compounds
typically remain unknown, however. Although clinical develop-
ment is possible without this knowledge, it is nonetheless highly
desirable and can facilitate further optimization of therapeutics,
as well as the prediction and monitoring of drug resistance.
Genomic and proteomic studies previously yielded a list of genes
implicated in the mode of action of oxaborole-1; this list included
CPSF3 and an adjacent glyoxalase, amplified in the genome in one
of three resistant clones, but no candidate was identified using both
approaches, and the list of candidates was too extensive for a sys-
tematic appraisal (24). Our results now support an interaction be-
tween oxaborole-1 and CPSF3. CPSF3 orthologs were also recently
identified as targets of another benzoxaborole (AN3661) active
against the malaria parasite, Plasmodium falciparum (19), and
Toxoplasma gondii (18). Thus, CPSF3 is a common target of ben-
zoxaboroles in the phylogenetically distant Apicomplexa and try-
panosomatids. Our identification of T. brucei CPSF3 as the target
of several benzoxaboroles now suggests that CPSF3 is also likely to
be a promising drug target, and the target of benzoxaboroles in
other protozoal parasites, including the other trypanosomatids, T.
cruzi and Leishmania spp; all CPSF3 catalytic site residues are
identical among these trypanosomatid sequences and the T. brucei
sequence (SI Appendix, Fig. S4A).
The metazoan CPSF complex recognizes polyadenylation sites
and controls pre-mRNA cleavage, polyadenylation, and tran-
scription termination (46); the CPSF3 component is the 3′ end
processing endonuclease (47). Notably, the complex is unlikely
to couple polyadenylation to transcription termination in trypa-
nosomatids, as transcription is almost exclusively polycistronic in
these cells (48). Polyadenylation and trans-splicing of adjacent
genes are coupled in trypanosomatids, however (42), and con-
sistent with this, CPSF3 knockdown disrupted both poly-
adenylation and trans-splicing in T. b. brucei (49). Accordingly,
inhibition of CPSF3 may explain perturbed methyl-donor me-
tabolism after acoziborole exposure (25), which may be because
Fig. 4. Molecular docking and editing of the T. b. brucei CPSF3 active site.
(A) The phylogenetic tree shows the relationship among CPSF3 proteins from
humans and protozoal parasites, all discussed in the text. (Right) Domain
structure for each protein. Domains: gray, metallo-β-lactamase (residues 48–
250 in T. brucei); green, β-CASP (residues 271–393 in T. brucei); blue, Zn-
dependent metallo-hydrolase (residues 408–463 in T. brucei); rust, C-
terminal (residues 502–746 in T. brucei). (B) Docking model for acoziborole
(yellow structure) bound to T. brucei CPSF3. Gray spheres, zinc atoms; dotted
lines, protein–ligand interactions. (C) Modified docking model illustrating a
steric clash between acoziborole (red patch) and a Tyr residue (beige) in
human CPSF3, in place of Asn232 in T. brucei CSPF3. The acoziborole mo-
lecular surface is otherwise represented in gray. Other binding site residues
that differ between the human and T. brucei enzymes are indicated. (D)
Dose–response curves with wild-type T. b. brucei (closed circles) or T. b.
brucei expressing Asn232His substituted CPSF3 (open squares and triangles,
two independent clones). Acoziborole EC50: wild-type, 0.31 ± 0.01 μM;
Asn232His, 1.59/1.44 ± 0.04/0.05 μM; 5.1/4.6-fold shift. Error bars, ±SD. (E)
Modified docking model illustrating a steric clash between acoziborole (red
patch) and the His residue (beige) in Asn232His substituted CPSF3.
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of reduced mRNA methylation as a result of a splicing defect.
CPSF3 also associates with the U1A snRNP splicing complex in
trypanosomatids (50).
Molecular docking studies and evidence from the Asn232His
mutant indicate how benzoxaboroles occupy the T. brucei CPSF3
active site, blocking pre-mRNA endonuclease activity. The
presence of a bulky Tyr side-chain in the human CPSF3 suggests
a steric clash with acoziborole, providing an explanation for the
selective activity and safety profile. Thus, our findings indicate
that the trypanocidal activities of acoziborole and AN11736 are a
result of specific perturbation of the polyadenylation and trans-
splicing activities directed by trypanosome CPSF3.
Unbiased genetic screens are remarkably powerful and can
sample thousands of genes for specific phenotypes. We as-
sembled a T. b. brucei overexpression library with optimized
genome coverage. Massive parallel screens confirmed the
mode of action of a known NMT inhibitor as inhibition of en-
docytosis and revealed the mode of action of the benzoxaboroles
as inhibition of pre-mRNA maturation. CPSF3 can now be
considered genetically and chemically validated as an important
antitrypanosomal drug target. Thus, our studies indicate that
both clinical and veterinary benzoxaboroles kill trypanosomes
by specifically inhibiting the parasite mRNA processing
endonuclease, CPSF3.
Materials and Methods
For details of T. brucei growth and manipulation, pRPaOEX plasmid library
assembly, T. brucei library assembly, overexpression screening, next gener-
ation sequencing data analysis, plasmid construction, EC50 assays, Western
blotting, microscopy, docking studies and Cas9-based editing, see SI Ap-
pendix, SI Materials and Methods.
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